Gholipur-Shahraki Tahereh, Vahdat Sahar, Seirafian Shiva, Pourfarzam Morteza, Badri Shirinsadat
Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
J Res Pharm Pract. 2022 Dec 14;11(2):80-86. doi: 10.4103/jrpp.jrpp_67_22. eCollection 2022 Apr-Jun.
One of the most common diseases with high morbidity and mortality rates is chronic kidney disease. Cardiovascular disease affects most patients with chronic kidney disorders, particularly patients undergoing dialysis; hence, appropriate prevention and management approaches are essential. This study aimed to evaluate the reduction of inflammatory biomarkers, especially homocysteine, by omega-3 fatty acids in peritoneal dialysis patients.
This study enrolled 60 peritoneal dialysis patients who met specified inclusion and exclusion criteria and were randomized to intervention or placebo groups. Omega-3 capsules were given at a dose of 3 g/d for 8 weeks. Inflammatory markers, including high-sensitivity C-reactive protein (hs-CRP), homocysteine, albumin, and lipid profile measured before and after the study.
Results of this trial revealed that the levels of homocysteine, hs-CRP, and albumin did not change significantly during the study. Analysis of lipid profiles before and after intervention showed omega-3 has no significant effect on the level of total cholesterol or low-density lipoprotein cholesterol; However, the level of triglyceride reduced remarkably ( = 0.002). In addition, serum levels of high-density lipoprotein cholesterol increased at the end of the study ( < 0.001).
Omega-3 does not seem to be able to change the inflammatory markers significantly, particularly homocysteine. More extensive trials must be conducted to better understand the impact of omega-3 on inflammatory and nutritional markers, particularly in peritoneal dialysis patients.
慢性肾脏病是发病率和死亡率极高的常见疾病之一。心血管疾病影响大多数慢性肾脏病患者，尤其是接受透析的患者；因此，采取适当的预防和管理方法至关重要。本研究旨在评估ω-3脂肪酸对腹膜透析患者炎症生物标志物，尤其是同型半胱氨酸的降低作用。
本研究纳入了60名符合特定纳入和排除标准的腹膜透析患者，并将其随机分为干预组或安慰剂组。给予ω-3胶囊，剂量为3 g/d，持续8周。在研究前后测量炎症标志物，包括高敏C反应蛋白（hs-CRP）、同型半胱氨酸、白蛋白和血脂谱。
该试验结果显示，在研究期间同型半胱氨酸、hs-CRP和白蛋白水平没有显著变化。干预前后血脂谱分析表明，ω-3对总胆固醇或低密度脂蛋白胆固醇水平没有显著影响；然而，甘油三酯水平显著降低（P = 0.002）。此外，在研究结束时血清高密度脂蛋白胆固醇水平升高（P < 0.001）。
ω-3似乎不能显著改变炎症标志物，尤其是同型半胱氨酸。必须进行更广泛的试验，以更好地了解ω-3对炎症和营养标志物的影响，特别是在腹膜透析患者中。
